April 02, 2025

HPV Testing Guidelines Updated for Head and Neck Carcinomas

New evidence expands recommendations for sinonasal squamous cell carcinoma and standardizes p16 immunohistochemistry interpretation.

Conexiant

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

April 01, 2025

Cracking the Bacterial Vaginosis Resistance Code

Investigators have identified distinct Gardnerella species with varying antibiotic resistance patterns, potentially guiding more effective treatment for recurrent bacterial vaginosis.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 31, 2025

95% of New Drugs Lack Lactation Safety Data, Study Finds

Only 5% of new drug approvals included human lactation data, according to researchers calling for improved lactation pharmacokinetics research for breastfeeding women.

Conexiant

March 28, 2025

FDA Clears First OTC Multi-STI Test

The diagnostic test for chlamydia, gonorrhea, and trichomoniasis offers 30-minute results.

Conexiant

March 27, 2025

Tampon Test May Detect Endometrial Cancer

New research from the Mayo Clinic shows promising results for a noninvasive methylated DNA marker panel that could reduce the number of unnecessary and painful biopsies in patients with abnormal uterine bleeding.

Conexiant

March 25, 2025

New Oral Antibiotic Targets Uncomplicated UTIs

FDA approves gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urinary tract infections in females aged 12 and older, based on phase III trial results.

Conexiant

March 25, 2025

Researchers Question Routine Urodynamic Testing

The researchers found that invasive urodynamic testing did not improve outcomes or cost-effectiveness in women with refractory overactive bladder symptoms.

Conexiant